MAP2K7 and cutaneous melanoma: The introduction of BRAF inhibitors like vemurafenib and dabrafenib, often used together with MEK inhibitors such as trametinib has significantly improved outcomes for patients carrying activating MAPK pathway mutations found in roughly 40–60% of cutaneous melanomas (Figure 1) [51,52,54].